Polyrizon Ltd

PLRZ

Market cap $15.1M

The Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies

Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing.

Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate.

Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product.

HONG KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (Nasdaq: PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™.

The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA

Collaboration aims to leverage Polyrizon's advanced proprietary intranasal delivery platform to support clinical development of Clearmind's drug candidate proprietary MEAI

T he Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd.

Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development Raanana, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the initiation of a key usability (Human Factors) study program for its lead product candidate, NASARIX™, an innovative intranasal allergy blocker designed for broad consumer use.

Company Remains Fully Committed to Advancing Its Core Intranasal Medical Pipeline, alongside examining new opportunities including in fields of aviation, AI and defense